Results 111 to 120 of about 13,549 (163)

Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma. [PDF]

Blood Adv
Abdallah N, Marar R, Yee C, Bodily A, Truman M, Wildes TM, Menser T, Weivoda M, Aug S, Smith B, Buadi F, Kapoor P, Dispenzieri A, Hayman S, Dingli D, Gonsalves W, Cook J, Zanwar S, Binder M, Kourelis T, Gertz M, Warsame R, Lin Y, Rajkumar SV, Dueck A, Kumar S.   +25 more
europepmc   +1 more source

Malaysian Expert Consensus Guidelines for the Diagnosis and Management of Multiple Myeloma: A Modified Delphi Approach. [PDF]

Malays J Med Sci
Gan GG, Wong LLL, Abdul Rahman MHF, Boo YL, Chew LP, Ho KW, Husin A, Rajasuriar JS, Tan SM, Tan SK, Tengku TAHKA.   +10 more
europepmc   +1 more source

Cardiovascular Adverse Events Associated With Carfilzomib, Bortezomib, and Ixazomib: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database With Anticancer Agents as the Reference Group. [PDF]

In Vivo
Fujiwara M, Nagano S, Uesawa Y, Uchida M, Muroi N, Shimizu T.   +5 more
europepmc   +1 more source

Correction: Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience. [PDF]

Front Oncol
Sretenovic A, Mitrovic M, Bukumiric Z, Vukosavljevic N, Kecman N, Jovanovic J, Fekete MD, Zaric E, Bila J.   +8 more
europepmc   +1 more source

Two cases of proteasome inhibitors related thrombotic microangiopathies and literature review. [PDF]

Thromb J
An N, Shi P, Chen C.
europepmc   +1 more source

Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'. [PDF]

J Cell Mol Med
europepmc   +1 more source

Proteome Profiling Reveals NQO2 Activity Contributing to Proteasome Inhibitor Resistance in Multiple Myeloma Cell Lines. [PDF]

Mol Cell Proteomics
Lee CY, Han S, Haertle L, Munawar U, Vogt C, Streubel J, Besse A, Besse L, Driessen C, Einsele H, Waldschmidt J, Kortüm M, Kuster B.   +12 more
europepmc   +1 more source

Disrupting adaptive proteostasis to overcome proteasome inhibitor resistance. [PDF]

Haematologica
Brioli A.
europepmc   +1 more source

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma. [PDF]

Clin Epigenetics
Han S, Haertle L, Munawar U, Truger M, Hainold AS, Lee CY, Kurian S, Verbruggen C, Nerreter S, Vogt C, Besant E, Rein N, Lehmann J, Köppel M, Tamamushi Y, Zhou X, Steinbrunn T, Haaf T, Küster B, Slaby O, Haferlach C, Einsele H, Rasche L, Waldschmidt J, Besse A, Driessen C, Besse L, Kortüm KM.   +27 more
europepmc   +1 more source